An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial

Clinical and Vaccine Immunology

Volumn 22, Issue 3, 2015, Pages 267-273

  Wressnigg, Nina ^a   Van Der Velden, Maikel V W ^a   Portsmouth, Daniel ^a   Draxler, Wolfgang ^a   O'Rourke, Maria ^a   Richmond, Peter ^b   Hall, Stephen ^c   McBride, William J H ^d   Redfern, Andrew ^e   Aaskov, John ^f,g   Barrett, P Noel ^a   Aichingera, Gerald ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d JAMES COOK UNIVERSITY   (Australia)

^e Linear Clinical Research Ltd QEII Medical Centre   (Australia)

^f QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^g AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED ROSS RIVER VIRUS VACCINE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ALPHAVIRUS INFECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTHRITIS; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE ECCHYMOSIS; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; LYMPHEDEMA; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; ROSS RIVER ALPHA VIRUS; ROSS RIVER VIRUS INFECTION; SYSTEMIC DISEASE; VERO CELL LINE; VOMITING; ADOLESCENT; ALPHAVIRUS INFECTIONS; ANIMAL; BLOOD; CHLOROCEBUS AETHIOPS; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; ROSS RIVER VIRUS; VACCINATION; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ALPHAVIRUS INFECTIONS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; AUSTRALIA; CERCOPITHECUS AETHIOPS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; ROSS RIVER VIRUS; VACCINATION; VACCINES, INACTIVATED; VERO CELLS; VIRAL VACCINES; YOUNG ADULT;

EID: 84923876575     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00546-14     Document Type: Article

References (30)

1. Aaskov J. 2009. Ross River virus: epidemic polyarthritis, p 631-644. In Barrett ADT, Stanberry LR (ed), Vaccines for biodefense and emerging and neglected diseases. Elsevier Academic Press, Amsterdam, The Netherlands.
2. Harley D, Sleigh A, Ritchie S. 2001. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin Microbiol Rev 14:909-932. http://dx.doi.org/10.1128/CMR.14.4.909-932.2001.
3. Smith DW, Speers DJ, Mackenzie JS. 2011. The viruses of Australia and the risk to tourists. Travel Med Infect Dis 9:113-125. http://dx.doi.org/10.1016/j.tmaid.2010.05.005.
4. Suhrbier A, La Linn M. 2004. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol 16:374-379. http://dx.doi.org/10.1097/01.bor.0000130537.76808.26.
5. Australian Government National Notifiable Diseases Surveillance System. 1991. National Notifiable Diseases Surveillance System: number of notifications of Ross River virus infection, received from State and Territory health authorities in the period of to 2013 and year-to-date notifications for 2014. Australian Government, Department of Health, Canberra, Australia.
6. Jacups SP, Whelan PI, Currie BJ. 2008. Ross River virus and Barmah Forest virus infections: a review of history, ecology, and predictive models, with implications for tropical northern Australia. Vector Borne Zoonotic Dis 8:283-297. http://dx.doi.org/10.1089/vbz.2007.0152.
7. Tong S. 2004. Ross River virus disease in Australia: epidemiology, socioecology and public health response. Intern Med J 34:58-60. http://dx.doi.org/10.1111/j.1444-0903.2004.00520.x.
8. Kramer LD, Chin P, Cane RP, Kauffman EB, Mackereth G. 2011. Vector competence of New Zealand mosquitoes for selected arboviruses. Am J Trop Med Hyg 85:182-189. http://dx.doi.org/10.4269/ajtmh.2011.11-0078.
9. Aaskov J, Williams L, Yu S. 1997. A candidate Ross River virus vaccine: preclinical evaluation. Vaccine 15:1396-1404. http://dx.doi.org/10.1016/S0264-410X(97)00051-0.
10. Holzer GW, Coulibaly S, Aichinger G, Savidis-Dacho H, Mayrhofer J, Brunner S, Schmid K, Kistner O, Aaskov JG, Falkner FG, Ehrlich H, Barrett PN, Kreil TR. 2011. Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine 29:4132-4141. http://dx.doi.org/10.1016/j.vaccine.2011.03.089.
11. Kistner O, Barrett N, Brühmann A, Reiter M, Mundt W, Savidis-Dacho H, Schober-Bendixen S, Dorner F, Aaskov J. 2007. The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine 25:4845-4852. http://dx.doi.org/10.1016/j.vaccine.2007.01.103.
12. Aichinger G, Ehrlich HJ, Aaskov JG, Fritsch S, Thomasser C, Draxler W, Wolzt M, Muller M, Pinl F, Van Damme P, Hens A, Levy J, Portsmouth D, Holzer G, Kistner O, Kreil TR, Barrett PN. 2011. Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial. Vaccine 29:9376-9384. http://dx.doi.org/10.1016/j.vaccine.2011.09.125.
13. Yu S, Aaskov JG. 1994. Development of a candidate vaccine against Ross River virus infection. Vaccine 12:1118-1124. http://dx.doi.org/10.1016/0264-410X(94)90182-1.
14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research 2007. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Washington, DC.
15. DeMeio JL, DeSanctis A, Thomas WJ. 1979. Persistence in humans of antibody after immunization with four alphavirus vaccines. Asian J Infect Dis 3:119-124.
16. Edelman R, Ascher MS, Oster CN, Ramsburg HH, Cole FE, Eddy GA. 1979. Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84). J Infect Dis 140:708-715. http://dx.doi.org/10.1093/infdis/140.5.708.
17. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. 2000. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 62:681-685.
18. Engler RJ, Mangiafico JA, Jahrling P, Ksiazek TG, Pedrotti-Krueger M, Peters CJ. 1992. Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine. J Med Virol 38:305-310. http://dx.doi.org/10.1002/jmv.1890380414.
19. Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ. 1996. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14:337-343. http://dx.doi.org/10.1016/0264-410X(95)00168-Z.
20. Steele KE, Reed DS, Glass PJ. 2007. Alphavirus Encephalitides, p 241-270. In Dembek ZF (ed), Medical aspects of biological warfare. Office of the Surgeon General, U.S. Army Medical Department Center and School, Borden Institute, Washington DC.
21. Halstead SB, Thomas SJ. 2010. Japanese encephalitis: new options for active immunization. Clin Infect Dis 50:1155-1164. http://dx.doi.org/10.1086/651271.
22. Heinz FX, Holzmann H, Essl A, Kundi M. 2007. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25:7559-7567. http://dx.doi.org/10.1016/j.vaccine.2007.08.024.
23. Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, Sisti M, Trent DW. 2011. An inactivated cell-culture vaccine against yellow fever. N Engl J Med 364:1326-1333. http://dx.doi.org/10.1056/NEJMoa1009303.
24. th ed. Saunders Elsevier, Philadelphia, PA.
25. Ehrlich HJ, Pavlova BG, Fritsch S, Pöllabauer EM, Löw-Baselli A, Obermann-Slupetzky O, Maritsch F, Cil I, Dorner F, Barrett PN. 2003. Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity. Vaccine 22: 217-223. http://dx.doi.org/10.1016/S0264-410X(03)00563-2.
26. Loew-Baselli A, Poellabauer EM, Pavlova BG, Fritsch S, Koska M, Bobrovsky R, Konior R, Ehrlich HJ. 2009. Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5 ml in adults aged 18-67 years. Hum Vaccin 5:551-556. http://dx.doi.org/10.4161/hv.5.8.8571.
27. Loew-Baselli A, Poellabauer EM, Pavlova BG, Fritsch S, Firth C, Petermann R, Barrett NP, Ehrlich HJ. 2011. Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme. Vaccine 29:7307-7319. http://dx.doi.org/10.1016/j.vaccine.2011.07.089.
28. Loew-Baselli A, Konior R, Pavlova BG, Fritsch S, Pöllabauer E, Maritsch F, Harmacek P, Krammer M, Barrett PN, Ehrlich HJ, FSMEIMMUN Study Group. 2006. Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies. Vaccine 24:5256-5263. http://dx.doi.org/10.1016/j.vaccine.2006.03.061.
29. Pöllabauer EM, Fritsch S, Pavlova BG, Löw-Baselli A, Firth C, Koska M, Maritsch F, Barrett PN, Ehrlich HJ. 2010. Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccine. Vaccine 28:4558-4568. http://dx.doi.org/10.1016/j.vaccine.2010.04.075.
30. Pöllabauer EM, Pavlova BG, Löw-Baselli A, Fritsch S, Draxler W, Firth C, Bosman J, Valenta B, Harmacek P, Maritsch F, Barrett PN, Ehrlich HJ. 2010. Comparison of immunogenicity and safety between two paediatric TBE vaccines. Vaccine 28:4680-4685. http://dx.doi.org/10.1016/j.vaccine.2010.04.047.